Grove Biopharma
Chicago, US · Founded 2020 · 4 known investors
Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions. The platform aims to produce therapeutics for patients with cancer, neurodegenerative diseases, and rare disorders.
Founders & leadership
GD
Geoffrey DuykCEO
Investors · 4
Funding
SEC filings, press & company announcements$30M disclosed across 1 of 2 rounds · 2025
- $30MSeries AApr 2025 · 3 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Grove Biopharma do?
- Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions. The platform aims to produce therapeutics for patients with cancer, neurodegenerative diseases, and rare disorders.
- Who are Grove Biopharma's investors?
- Grove Biopharma's investors include DCVC (Data Collective), DCVC Bio, InVivium Capital, Portal Innovations.
- How much funding has Grove Biopharma raised?
- Grove Biopharma has disclosed $30M raised across 1 of its 2 known rounds.
- Where is Grove Biopharma headquartered?
- Grove Biopharma is headquartered in Chicago, US.